SCHEMBL14948673

SCHEMBL14948673

Cc1ccc(NC(=O)NN2C(=O)NC3(CCC(C)CC3)C2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 14/20 1.00
LMNA P02545 1/20 0.59
TDP1 Q9NUW8 1/20 0.53
PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23129558 0.80 FPR2 (0.67) FPR2LMNAPKM
SCHEMBL20882942 0.80 FPR2 (0.66) FPR2LMNATDP1PKM
SCHEMBL16008139 0.77 FPR2 (1.00) FPR2
SCHEMBL14935439 0.77 FPR2 (1.00) FPR2
SCHEMBL19201531 0.76 FPR2 (1.00) FPR2
SCHEMBL14935681 0.76 FPR2 (1.00) FPR2
SCHEMBL14935504 0.76 FPR2 (0.81) FPR2
SCHEMBL14951275 0.75 FPR2 (1.00) FPR2
SCHEMBL14938341 0.75 FPR2 (0.74) FPR2
SCHEMBL19201552 0.71 FPR2 (1.00) FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110279684-B Use of formyl peptide receptor 2 agonists for the treatment of ocular inflammatory diseases 阿勒根公司 2023-02-28 CN claimed
US-10899780-B2 Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases ALLERGAN, INC. (US) 2021-01-26 US claimed
US-20210008085-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES ALLERGAN INC (US) 2021-01-14 US claimed
US-20190153004-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES ALLERGAN, INC. 2019-05-23 US claimed
EP-2964214-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES ALLERGAN, INC. (US) 2016-01-13 EP claimed
EP-2964213-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES ALLERGAN, INC. (US) 2016-01-13 EP claimed
WO-2014138037-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES ALLERGAN, INC. (US) 2014-09-12 WO claimed
WO-2014138046-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES ALLERGAN, INC. (US) 2014-09-12 WO claimed
US-20140256684-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES ALLERGAN, INC. (US) 2014-09-11 US claimed
US-20140256685-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES ALLERGAN, INC. (US) 2014-09-11 US claimed
EP-3795148-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES ALLERGAN, INC. (US) 2021-03-24 EP disclosed
EP-3795148-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES ALLERGAN, INC. (US) 2021-03-24 EP disclosed
US-10899780-B2 Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases ALLERGAN, INC. (US) 2021-01-26 US disclosed
US-20210008085-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES ALLERGAN INC (US) 2021-01-14 US disclosed
US-20210008085-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES ALLERGAN INC (US) 2021-01-14 US disclosed
US-20140256684-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES ALLERGAN, INC. (US) 2014-09-11 US disclosed
US-20140256684-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES ALLERGAN, INC. (US) 2014-09-11 US disclosed
US-8492556-B2 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-20130123215-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 US disclosed
WO-2013071203-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008085-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES FPR2, FPR1, FPR3 FPR2 1/4885LMNA 3347/4885TDP1 3406/4885
US-20130123215-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR2, FPR3 FPR2 2/4885LMNA 3779/4885TDP1 3272/4885
US-20140256685-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES FPR2, FPR1, FPR3 FPR2 1/4885LMNA 3347/4885TDP1 3406/4885
US-20190153004-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES FPR2, FPR1, FPR3 FPR2 1/4885LMNA 4475/4885TDP1 4140/4885
US-20140256684-A1 USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES FPR2, FPR1, FPR3 FPR2 1/4885LMNA 4475/4885TDP1 4140/4885
US-10899780-B2 Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases FPR2, FPR1, FPR3 FPR2 1/4885LMNA 4475/4885TDP1 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.